CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Open-market sale President sold 11,833 shares at an average $20.09 ($237,760)
- 4 Open-market sale Chief Scientific Officer sold 10,307 shares at an average $20.14 ($207,629)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President sold 10,000 shares at an average $22.27 ($222,678)
- 4 Grant or award Chief Scientific Officer acquired 91,354 shares (grant or award)
- 4 Grant or award President acquired 161,092 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 244,800 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 101,957 shares (grant or award)
- 4 Grant or award General Counsel acquired 40,783 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 16,313 shares (grant or award)
- 4 Open-market sale President sold 10,000 shares at an average $24.15 ($241,515)
- 4 Open-market sale President sold 10,000 shares at an average $21.02 ($210,228)
- 4 Open-market sale President sold 12,500 shares at an average $22.77 ($284,683)
- 4 Open-market sale President sold 24,874 shares at an average $23.62 ($587,403)
- 4 Open-market sale President sold 12,500 shares at $23.51 ($293,879)
- 4 Open-market sale President sold 22,500 shares at an average $22.45 ($505,186)
- 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 100,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 5 of 13 · 252 filings